NTRK2 _ Trk_B _ TRKB Antibody
- Known as:
- NTRK2 _ Trk_B _ TRKB Antibody
- Catalog number:
- 10047-R107
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- NTRK2 _ Trk_B TRKB Antibody
Related genes to: NTRK2 _ Trk_B _ TRKB Antibody
- Gene:
- NTRK2 NIH gene
- Name:
- neurotrophic receptor tyrosine kinase 2
- Previous symbol:
- -
- Synonyms:
- TRKB
- Chromosome:
- 9q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-18
- Date modifiied:
- 2018-07-09
Related products to: NTRK2 _ Trk_B _ TRKB Antibody
Related articles to: NTRK2 _ Trk_B _ TRKB Antibody
- Neuropsychiatric dysfunction is increasingly being acknowledged as a disabling complication of non-alcoholic steatohepatitis (NASH), but there are no therapeutic approaches. We investigated in the present study the neuroprotective effectiveness of naringenin, a citrus flavonoid with known anti-inflammatory and neurotrophic effects, in a murine NASH model induced by an 8-week methionine-choline-deficient (MCD) diet. Male C57BL/6 mice (n = 8/group) were treated with naringenin (50 mg/kg/day, i.p.) during the final 4 weeks. In behavioral tests, naringenin counteracted cognitive impairment in novel object recognition, reduced anxiety in both open field and elevated plus maze paradigms, and decreased immobility in the forced swim test, indicating antidepressant-like activity. Mechanistically, naringenin restored hippocampal apoptotic balance, normalizing the MCD diet-induced upregulation and downregulation. Notably, while the MCD diet suppressed both and expression, naringenin treatment partially restored (but not ) mRNA levels, implicating -related neuroplasticity in its therapeutic effects. The research highlights naringenin's neuroprotective functions and its multitarget therapeutic potential in the MCD diet model of steatohepatitis, as evidenced by its effects on hippocampal gene expression and behavioral outcomes Additional studies are needed to validate the effect in clinical settings and establish optimal dosing regimens. - Source: PubMed
Publication date: 2026/04/21
Sahebi Mohammad-HadiNasehi MohammadMoslehi AzamZarrindast Mohammad-RezaEbrahimi-Ghiri Mohaddeseh - The use of next-generation sequencing (NGS) in clinical investigations has enabled the identification of actionable biomarkers across tumor histologies, paving the way for the development of pan-tumor therapies. Gene fusions involving , and have emerged as rare yet clinically significant oncogenic drivers in a wide range of both pediatric and adult tumors due to high response rates to FDA-approved targeted therapies. Consequently, widespread testing for fusions is recommended across tumor types. However, data on fusions in cancer have predominantly been sourced from academic institutions and reference laboratories. - Source: PubMed
Publication date: 2026/04/02
Dowdell Alexa KWard Thomas RHamilton Lauren TWeerasinghe Roshanthi KSchnettler EricaSathyan PratheeshRoos AlisonWagner Josiah TWelle JohnMeng Ryan CBartlett Alexandra QBifulco Carlo BPiening Brian D - Irritable bowel syndrome (IBS) associated with early-life stress (ELS) commonly manifests as anxiety and visceral hypersensitivity. However, the pathogenic mechanisms underlying these effects are not fully understood. This study aims to investigate the role of brain-derived neurotrophic factor (BDNF) as a key mediator of ELS-induced changes through the brain-gut axis. - Source: PubMed
Zhao HongyuChen FeixueLi BingFu ShiChenZuo XiuliZhang Liming - Inflammatory bowel disease (IBD) is a chronic gastrointestinal disorder with a high incidence of anxiety and depression. However, the underlying mechanisms of these symptoms remain to be fully elucidated. This study investigated the effects and mechanisms of a 20% ethanolic extract of leaves (EPJ) on dextran sulfate sodium (DSS)-induced colitis and depression-like behaviors. The physiological compounds identified in the EPJ were citric acid, chlorogenic acid, caffeic acid, fukinolic acid, 3,5-dicaffeoylquinic acid, quercetin 3-O-β-D-glucose-6″-acetate, 4,5-dicaffeoylquinic acid, kaempferol-3-O-(6″-acetyl)-β-glucopyranoside, and pedunculoside. EPJ significantly alleviated DSS-induced colitis, as evidenced by improvements in body weight loss (87.41% vs. 76.02% in the DSS group), colon length (5.75 vs. 4.34 cm), intestinal permeability (52.80 vs. 163.01 μg/mL), and myeloperoxidase (MPO) activity (0.24 vs. 0.67 U/mg) ( < 0.05). Histological analysis further confirmed recovery of goblet cells and attenuation of muscle layer thickening. EPJ also reversed DSS-induced gut microbiota dysbiosis and contributed to the restoration of microbial homeostasis. Behavioral assessments showed that EPJ effectively ameliorated depression-like behaviors. EPJ improved antioxidant systems in colon and brain tissues by modulating malondialdehyde (MDA) levels and reduced glutathione (GSH) and superoxide dismutase (SOD) activity. EPJ further upregulated tight junction protein expression and suppressed TLR4/NF-κB inflammatory pathway activation in both colon and brain tissues. Moreover, EPJ modulated serum stress-related hormones, normalized hypothalamic-pituitary-adrenal (HPA) axis dysregulation, regulated the BDNF/TrkB signaling pathway, and modulated tryptophan-kynurenine metabolism. Collectively, these findings suggest that EPJ exerts protective effects against DSS-induced colitis and depression-like behaviors. - Source: PubMed
Publication date: 2026/04/04
Na Hwa RangLee Hyo LimChoi Hye JiHeo Yu MiJu Yeong HyeonKim Hyun-JinHeo Ho Jin - Although fusions are actionable targets for a wide array of solid tumors, treatment-relevant biomarkers are heterogeneous and remain incompletely characterized for real-world fusion-positive populations. This retrospective cohort study provides a detailed molecular characterization of functional fusions and identifies biomarker associations in a real-world pan-cancer population. - Source: PubMed
Publication date: 2026/03/24
Zhou JianuoZong QinglanSun RuijiaWang XiangleiHuang MengliYu Wenyan